EDGAR·FLOW

Viridian Therapeutics, Inc.\DE — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Viridian announced positive Phase 1 results for VRDN-008, a subcutaneous FcRn inhibitor licensed from Paragon Therapeutics, demonstrating 74% peak IgG reduction sustained through 8 weeks with a 15–18 day half-life (6x longer than first-gen Fc fragments), supporting every-8-week dosing via the Enable enFuse injector. The company plans to initiate a registrational trial in myasthenia gravis in mid-2027 (pending regulatory feedback) with Q4W and Q8W dosing arms, and to expand development into multiple autoimmune diseases; no serious adverse events or dose-limiting toxicities were reported.
Why this rating

Lead program shows clinically meaningful differentiation (every-8-week dosing, deep/sustained suppression, favorable safety) and clear path to registrational trial in validated indication. Early-stage binary but de-risks pipeline for $943M company; market opportunity described as multi-billion-dollar per indication.

Tradability signal
NO TRADE

No trade: positive news with only +1.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.60% over 4 hrs, n=396). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$28.50 ▼ 2.55%
at our read · unknown
$29.25
+10 min · unknown
$29.03 ▼ 0.74%
+30 min · unknown
$29.73 ▲ 1.64%
+1 hr · unknown
$29.63 ▲ 1.32%
+4 hrs · unknown
$30.24 ▲ 3.40%

The stock had already moved +2.61% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ VRDN · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.